Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
ISRN Hematol ; 2012: 139862, 2012.
Article in English | MEDLINE | ID: mdl-23316378

ABSTRACT

This prospective study assessed the quality of life of patients with homozygous transfusion-dependent beta-thalassemia in Greece receiving three different iron chelation treatments. Patients enrolled were receiving one of the following chelation therapies: deferoxamine (n = 21), deferasirox (n = 75), or deferoxamine in combination with deferiprone (n = 39). The three groups were compared in terms of their quality of life, satisfaction and adherence to treatment, control of their health, and self-esteem through the completion of five questionnaires. A higher percentage of patients receiving deferoxamine felt that their treatment negatively influenced their body and skin appearance and limited their ability to work, attend school, and perform daily tasks (P = 0.0066). The adherence to treatment rate and self-esteem were the lowest in the deferoxamine group (P < 0.05). The deferoxamine group also had the lowest physical component summary score in the SF-36 questionnaire (P = 0.014). This study suggests that the quality of life of beta-thalassemia patients receiving chelation therapy is dependent on the type of iron chelation treatment they receive. The study provides insight into important factors associated with the quality of life of these patients, which are essential for developing a more suitable clinical support team and counseling in order to maximize the treatment benefits for these patients in daily clinical practice.

2.
Anticancer Res ; 31(3): 831-42, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21498703

ABSTRACT

BACKGROUND: In order to reduce toxicity and to enhance anticancer activity of nitrogen mustards, three hybrid steroidal esters were synthesized and tested in vitro against human pancreatic cancer cells expressing uridine phosphorylase (UPase). The inhibition potency against a target protein implicated in the chemotherapy of solid tumors, such as UPase, is of fundamental importance in the design and synthesis of new anticancer drugs. MATERIALS AND METHODS: MTT colorimetric assay and molecular docking were employed for the in vitro and in silico drug evaluation, respectively. RESULTS: A difference in cell sensitivity was found, which followed the known different UPase expression in the cell lines. Molecular docking studies on UPase protein, revealed the tested compounds to be bound to the binding cavity of the protein, with different affinity. Between the two D-modified compounds, the D-homo-aza (lactam)-hybrid compound (C2) was found to interact with the protein in a more efficient way. CONCLUSION: The molecular docking data were in accordance with the in vitro results, where the lactam steroid alkylator showed significantly higher cytostatic and cytotoxic activity than the non-D-modified compounds, which also correlated with the level of UPase expression in the pancreatic cancer cells.


Subject(s)
Alkylating Agents/pharmacology , Antineoplastic Agents/pharmacology , Computational Biology , Molecular Targeted Therapy , Steroids/pharmacology , Uridine Phosphorylase/antagonists & inhibitors , Alkylating Agents/chemistry , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , Fluorouracil/chemistry , Fluorouracil/metabolism , Humans , Ligands , Models, Molecular , Neoplasm Proteins/chemistry , Neoplasm Proteins/metabolism , Steroids/chemistry , Thermodynamics , Thiouracil/analogs & derivatives , Thiouracil/chemistry , Thiouracil/metabolism , Uridine Phosphorylase/chemistry , Uridine Phosphorylase/metabolism
3.
Breast Cancer Res Treat ; 97(1): 17-31, 2006 May.
Article in English | MEDLINE | ID: mdl-16319980

ABSTRACT

The sensitivity of breast neoplasms to hormonal control provides the basis of novel investigational treatments with steroidal alkylators. An androsterone D-lactam steroidal ester, the 3beta-hydroxy-13alpha-amino-13,17-seco- 5alpha-androstan-17-oic-13,17-lactam, p-bis(2-chloroethyl)amino phenyl acetate (lactandrate) was synthesized and tested for antitumor activity against six human breast cancer cell lines in vitro and against two murine and one xenograft mammary tumors in vivo. A docking study on the binding interactions of lactandrate with the ligand-binding domain (LBD) of estrogen receptor-alpha (ERalpha) was inquired. In vitro testing of lactandrate cytostatic and cytotoxic activity was performed on T47D, MCF7, MDA-MB-231, BT-549, Hs578T, MDA-MB-435 breast adenocarcinoma human cell lines. In vivo testing was performed on two murine mammary tumors, the MXT tumor and CD8F1 adenocarcinoma, as well as on human mammary carcinoma MX-1 xenograft. Molecular modeling techniques were adopted to predict a possible location and interaction mode of the molecule into LBD. Lactandrate induced significantly high antitumor effect against all tested in vitro and in vivo models. The cell lines with positive ER expression found to be significantly more sensitive to lactandrate. Moreover, lactandrate found to be positioned inside the binding cavity with its steroidal moiety, whilst the alkylating moiety protrudes out of receptor's pocket. Lactandrate produced important anticancer activity on breast cancer in vitro and in vivo. Some correlation between ER and lactandrate effect was demonstrated. Docking studies provide the basis for the structure-based design of improved steroidal alkylating esters for the treatment of estrogen-related cancers.


Subject(s)
Alkylating Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Azasteroids/therapeutic use , Homosteroids/therapeutic use , Mammary Neoplasms, Experimental/drug therapy , Secosteroids/therapeutic use , Adenocarcinoma/drug therapy , Androsterone/therapeutic use , Animals , Cell Proliferation/drug effects , Estrogen Receptor alpha/metabolism , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Molecular Structure , Tumor Cells, Cultured/drug effects
4.
Farmaco ; 60(10): 826-9, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16139280

ABSTRACT

The p-[N,N-bis(2-chloroethyl)amino]phenylacetic acid esters of hecogenin and aza-homo-hecogenin have been prepared and their antineoplastic activity was evaluated against two basic drug screening systems in rodents, P388 lymphocytic and L1210 lymphoid murine leukemias. Among the compounds tested, the p-[N,N-bis(2-chloroethyl)amino]phenylacetic acid ester of aza-homo-hecogenin was appeared to possess a significant higher antileukemic effect. These results support that the alkylating esters of hecogenin produce important antitumor activity as well as, indicate that the aza-homo-hecogenin ester exhibits significantly higher activity due to lactam group (-NHCO-) modification.


Subject(s)
Antineoplastic Agents , Azasteroids , Leukemia L1210/drug therapy , Leukemia P388/drug therapy , Phenylacetates , Sapogenins , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Azasteroids/chemistry , Azasteroids/pharmacology , Azasteroids/therapeutic use , Drug Screening Assays, Antitumor , Mice , Molecular Structure , Phenylacetates/chemistry , Phenylacetates/pharmacology , Phenylacetates/therapeutic use , Sapogenins/chemistry , Sapogenins/pharmacology , Sapogenins/therapeutic use , Structure-Activity Relationship
5.
Melanoma Res ; 15(4): 273-81, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16034305

ABSTRACT

Evidence indicating that hybrid steroid compounds of anti-cancer agents produce reduced toxicity, significantly lower than the cytotoxic components alone, and increased anti-cancer activity has prompted the design and development of such steroids, mostly alkylating esters. We investigated the in-vitro and in-vivo activity of a homo-aza-steroidal alkylating ester (HASE), in comparison with dacarbazine (DTIC), cisplatin (CPDD), carmustine (BCNU) and semustine (MeCCNU), in the treatment of malignant melanoma. Cytotoxicity was assessed in vitro by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using a panel of six human malignant melanoma cell lines, with or without the presence of rat liver microsome assay. B16 melanoma-bearing mice were used to evaluate in vivo the anti-tumour activity of the tested compounds. In all cases of in-vitro screening, HASE displayed a significantly higher (P<0.0001) cytostatic and cytotoxic effect than DTIC, BCNU and MeCCNU, but produced significantly lower (P<0.0001) activity than CPDD. HASE exhibited a significantly smaller range than CPDD between concentration levels that produced growth arrest and those that induced a cytotoxic effect against melanoma cells in vitro. The anti-tumour activity of HASE in B16 melanoma-bearing mice, as determined by tumour growth rate inhibition (<42%) and percentage survival prolongation (treated versus control, 167%), was significantly superior (P<0.001) to that achieved by DTIC, BCNU and MeCCNU and was equal to that of CPDD. HASE exhibited a toxicity similar to that of DTIC, BCNU and MeCCNU, but significantly lower than that of CPDD. It can be concluded that HASE displays significant in-vitro and in-vivo activity in the treatment of melanoma.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacology , Azasteroids/pharmacology , Melanoma, Experimental/drug therapy , Nitrogen Mustard Compounds/pharmacology , Animals , Antineoplastic Agents, Alkylating/therapeutic use , Azasteroids/therapeutic use , Cell Line, Tumor , Cisplatin/pharmacology , Cisplatin/therapeutic use , Dacarbazine/pharmacology , Dacarbazine/therapeutic use , Drug Screening Assays, Antitumor , Esters/pharmacology , Female , Humans , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Neoplasm Transplantation , Nitrogen Mustard Compounds/therapeutic use
6.
Br J Haematol ; 128(3): 343-50, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15667536

ABSTRACT

Summary NSC290205 (A) is an hybrid synthetic antineoplastic ester that is a combination of a d-lactam derivative of androsterone and an alkylating derivative of N,N-bis(2-chloroethyl)aniline. We tested NSC290205 for synergistic antileukaemic activity with adriamycin (ADR), (i) in vitro against the human lymphoid leukaemia cell lines: CCRF-CEM, MOLT-4, and RPMI-8226, (ii) in vivo against P388 lymphocytic and L1210 lymphoid murine leukaemias (at incipient and advanced phase). Our results indicated significant cytostatic and cytotoxic synergy of NSC290205 and ADR in vitro. We further examined these results in vivo by replacing cyclophosphamide in the standard CHOP (cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone) regimen with NSC290205 (AHOP) and comparing the efficiency of these two regimens in vivo. Although treatment of P388 and L1210 with cyclophosphamide or NSC290205 alone yielded equivalent results, AHOP produced a clear benefit for survival compared with CHOP against advanced leukaemias, confirming the in vitro observations [higher percentage increase in median lifespan of treated animals over the untreated (control): 188% and 239% in L1210, 308% and 353% in P388, P < 0.01, for CHOP and AHOP respectively]. AHOP also proved to be more genotoxic and cytostatic than CHOP, inducing higher sister chromatid exchange levels and cell division delays on P388 cells in vivo. NSC290205 showed superior antineoplastic potential against lymphoid leukaemia and significant synergy with ADR, producing an excellent therapeutic outcome.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Leukemia, Experimental/drug therapy , Leukemia, Lymphoid/pathology , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Azasteroids/administration & dosage , Cell Death/drug effects , Cyclophosphamide/therapeutic use , Doxorubicin/administration & dosage , Doxorubicin/therapeutic use , Drug Evaluation, Preclinical , Drug Synergism , Humans , Leukemia, Experimental/pathology , Male , Mice , Mice, Inbred Strains , Neoplasm Transplantation , Nitrogen Mustard Compounds/administration & dosage , Prednisone/therapeutic use , Survival Analysis , Tumor Cells, Cultured , Vincristine/therapeutic use
7.
Invest New Drugs ; 21(1): 47-54, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12795529

ABSTRACT

In order to reduce toxicity and to increase antineoplastic activity, steroid molecules were utilized as biological vectors for chemotherapeutic agents. Several modified steroid compounds as 17beta-acetamido and D-homo-aza steroids that contain the NHCO group outside or inside D steroid ring, respectively, were used in the synthesis of steroidal esters carrying alkylating moieties. As it has been reported previously, several of these compounds produced important both antileukemic and antitumor results. In this work, we comparatively study, evaluate, and conclude on the acute toxicity on mice, the in vivo antileukemic activity against P388 and L1210 murine leukemias, as well the in vitro antileukemic effect on three well established human leukemia cell lines (K562, MOLT-4, ML-1) of eight D-homo-aza-steroidal (HASE) and the corresponding steroidal 17beta-amido-esters (SAE) of three alkylating molecules. The compound screening indicated that HASE induced lower acute toxicity and significant higher antileukemic effect than SAE, both in vivo and in vitro. Furthermore, the structure of the homo-aza-steroidal vector seems to be a determinant of the toxicity and antineoplastic activity of the esters. Conclusively, HASE presented low acute toxicity but significant high antileukemic activity. These results point out that HASE may be of important therapeutic efficacy in the treatment of leukemia in humans.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Azasteroids/therapeutic use , Animals , Antineoplastic Agents, Alkylating/chemical synthesis , Antineoplastic Agents, Alkylating/toxicity , Azasteroids/chemical synthesis , Azasteroids/toxicity , Cell Line, Tumor , Drug Screening Assays, Antitumor , Esters , Female , Humans , Injections, Intraperitoneal , Lethal Dose 50 , Leukemia, Experimental , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Structure-Activity Relationship , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...